GE Healthcare does molecular breast imaging distribution deal with Dilon

Imaging company Dilon Diagnostics has landed a partnership to distribute a molecular breast imaging system from GE Healthcare ($GE) in select, undisclosed global geographies. The offering is intended to complement Dilon's own molecular imaging offerings.

The Newport News, VA-based company primarily is devoted to marketing imaging products globally that were developed in partnership with the U.S. Department of Energy's Thomas Jefferson National Accelerator Facility as well as medical universities.

Discovery NM750b Molecular Breast Imaging system--Courtesy of GE

"We are excited to make the Discovery NM750b breast imaging system further available and to benefit from Dilon's global and solid network of sales representatives," said Nathan Hermony, Nuclear Imaging global business manager for GE Healthcare, in a statement. "GE believes strongly in this advanced technology and the potential for this type of imaging to improve breast cancer diagnosis. Dilon Diagnostics resources will bring further the education and acceptance of molecular breast Imaging."

GE's Discovery NM750b Molecular Breast Imaging system is based on Cadmium Zinc Telluride (CZT) detectors, which enable breast imaging up close and right up to the chest wall. It's intended to detect early cancer and small tissue changes. The GE system is designed for breast cancer detection and treatment monitoring; it boasts high sensitivity even among patients with dense breast tissue, which are among the most difficult for accurate cancer detection and are also at a higher risk for breast cancer.

Dilon's own Molecular Imaging System is its cornerstone product and is designed to be used to image small body parts, including the breast, thyroid parathyroid and bone. It's also designed for use in difficult to diagnose cases where there is a suspicion of cancer as well as for hard-to-interpret cases.

"We are very pleased to associate with GE Healthcare, a world leader in innovation, in the fight against breast cancer," says Dilon chairman and CEO Robert Moussa. "This relationship will enable us to expand our product portfolio and offer a complete spectrum of BSGI/MBI solutions to better meet the needs of our customers."

- here is the announcement

Read more on